Author: Ravi Shankar

Accomplished executive to lead strategy and corporate development function driving TransUnion’s next chapter of global growth and innovation

CHICAGO, Sept. 28, 2026 (GLOBE NEWSWIRE) — Malte Bernholz will join TransUnion (NYSE: TRU) as Executive Vice President, Chief Strategy and Corporate Development Officer, effective today.

In this newly created role, Bernholz will lead TransUnion’s Enterprise Strategy and Corporate Development function, aligning the organization around a long-term strategy to drive global innovation and scale. He will report to TransUnion President and Chief Executive Officer Chris Cartwright and serve on the executive leadership team.

“TransUnion is expanding how we use data, analytics and technology to drive growth from our broader range of solutions across markets globally, building up our leadership in Credit,” said Cartwright. “I’m confident Malte will strengthen our ability to shape strategy, execute enterprise change, monetize our assets and acquire new capabilities.”

Bernholz will join TransUnion with significant experience leading corporate strategy, M&A and large-scale organizational transformation across global software businesses, private equity investments, and top-tier consulting. Most recently at Adobe, he oversaw enterprise-wide growth strategy across the company’s creativity, productivity and customer experience businesses, and founded and scaled its new product incubator. Prior to Adobe, he served as Vice President of Corporate Strategy Consulting at EMC, as well as Chief Operating Officer at iVize and a consultant at McKinsey & Company. He earned an M.S. from Institut Polytechnique de Grenoble.

“Driving growth in the era of agentic AI requires every organization to develop strategy, plan and execute differently to meet customer needs,” said Bernholz. “I’m excited to join TransUnion at the most innovative point in its history and accelerate how we scale that innovation around the world.”
  
About TransUnion (NYSE: TRU)
TransUnion is a global information and insights company with over 13,000 associates operating in more than 30 countries. We make trust possible by ensuring each person is reliably represented in the marketplace. We do this with a Tru™ picture of each person: an actionable view of consumers, stewarded with care. Through our acquisitions and technology investments we have developed innovative solutions that extend beyond our strong foundation in core credit into areas such as marketing, fraud, risk and advanced analytics. As a result, consumers and businesses can transact with confidence and achieve great things. We call this Information for Good^® — and it leads to economic opportunity, great experiences and personal empowerment for millions of people around the world. http://www.transunion.com/business.

Contact	Dave Blumberg
	TransUnion
E-mail	david.blumberg@transunion.com
Telephone	312-972-6646

• Eton Pharmaceuticals now holds exclusive commercialization rights for IMPAVIDO in the United States
• Eton has integrated full Eton Cares^® patient support, including $0 co-pay for eligible commercially insured patients and expanded patient assistance programs
• Centralized distribution through Anovo Specialty Pharmacy is designed to simplify access and therapy initiation for outpatient prescribing, inpatient consignment, and urgent access coordination

DEER PARK, Ill., Sept. 28, 2026 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the Company has launched IMPAVIDO^® (miltefosine) capsules.

“We are excited to be relaunching IMPAVIDO and making Eton Cares available to all patients. By bringing IMPAVIDO into Eton’s rare disease commercial infrastructure, we can pair this important therapy with high-touch services designed to help support healthcare providers and expand access for patients. We believe this comprehensive approach will help ensure that patients who need IMPAVIDO can access and initiate treatment without unnecessary delays. We are also working to expand hospital on-site availability across the United States through our consignment inventory stocking program,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.

Clinicians seeking to prescribe IMPAVIDO can e-prescribe by selecting Anovo #5 (Memphis) or fax a patient referral form to 855-813-2039. Patients with questions regarding their prescription or healthcare providers can call Anovo at the dedicated IMPAVIDO line 877-469-4078.

Hospital pharmacies seeking IMPAVIDO for inpatient use may contact Anovo Specialty Pharmacy to establish access through the hospital network.

For urgent or time-sensitive patient needs, Anovo will coordinate an emergency access pathway with treating clinicians, CDC representatives, and hospital pharmacies. The pathway is designed to evaluate the fastest available source of product and delivery option based on the patient’s need-by time and the treating institution’s location.

Additional product details can be found on the product website, www.impavidous.com.

Important Safety Information for IMPAVIDO

INDICATION

IMPAVIDO® (miltefosine) is an antileishmanial drug indicated in adults and adolescents ≥12 years of age weighing ≥30 kg (66 lbs) for treatment of:

• Visceral leishmaniasis due to Leishmania donovani.
• Cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis.
• Mucosal leishmaniasis due to Leishmania braziliensis.

Limitations of Use: Leishmania species evaluated in clinical trials were based on epidemiologic data. There may be geographic variation in the response of the same Leishmania species to IMPAVIDO. The efficacy of IMPAVIDO in the treatment of other Leishmania species has not been evaluated.

IMPORTANT SAFETY INFORMATION

Contraindications

IMPAVIDO is contraindicated in pregnancy because it may cause fetal harm; in patients with Sjögren-Larsson syndrome; and in patients with hypersensitivity to miltefosine or any component of the formulation.

Warnings and Precautions

Embryo-Fetal Toxicity: IMPAVIDO may cause fetal harm when administered during pregnancy. Obtain a pregnancy test before initiating therapy in females of reproductive potential. Advise females of reproductive potential to use effective contraception during treatment and for 5 months after completion of therapy. If vomiting or diarrhea occurs during treatment, oral contraceptive effectiveness may be reduced; advise use of an additional non-hormonal contraceptive method.

Reproductive Effects: Miltefosine caused impaired fertility in animal studies. The potential effects on human fertility have not been adequately evaluated.

Renal Effects: Monitor serum creatinine during treatment and for 4 weeks after completion of therapy.

Hepatic Effects: Monitor liver transaminases and bilirubin during treatment.

Gastrointestinal Effects: Vomiting and diarrhea are common and may result in dehydration. Encourage adequate fluid intake during treatment.

Thrombocytopenia: Monitor platelet counts during therapy in patients treated for visceral leishmaniasis.

Stevens-Johnson Syndrome: Stevens-Johnson syndrome has been reported. Discontinue IMPAVIDO if an exfoliative or bullous rash develops.

Adverse Reactions

The most common adverse reactions (≥2%) are nausea, vomiting, diarrhea, headache, decreased appetite, dizziness, abdominal pain, pruritus, somnolence, elevated transaminases, and elevated serum creatinine.

To report a suspected adverse event related to IMPAVIDO, contact Eton Pharmaceuticals, Inc. at 1-855-224-0233 or the U.S. Food and Drug Administration (FDA) at www.fda.gov/MedWatch or call 1-800-FDA-1088.

Please see Full Prescribing Information, including Boxed Warning regarding Embryo-Fetal Toxicity.

About Eton Pharmaceuticals

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eleven commercial rare disease products: KHINDIVI^® (hydrocortisone), INCRELEX^® (mecasermin), ALKINDI SPRINKLE^® (hydrocortisone), DESMODA^™ (desmopressin acetate), GALZIN^® (zinc acetate), HEMANGEOL^® (propranolol hydrochloride), PKU GOLIKE^®, IMPAVIDO^® (miltefosine), Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: AMGLIDIA^® (glyburide), ASN-001, ET-700, ET-800, and ZENEO^® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

• Eton Pharmaceuticals now holds exclusive commercialization rights for IMPAVIDO in the United States
• Eton has integrated full Eton Cares^® patient support, including $0 co-pay for eligible commercially insured patients and expanded patient assistance programs
• Centralized distribution through Anovo Specialty Pharmacy is designed to simplify access and therapy initiation for outpatient prescribing, inpatient consignment, and urgent access coordination

DEER PARK, Ill., Sept. 28, 2026 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the Company has launched IMPAVIDO^® (miltefosine) capsules.

“We are excited to be relaunching IMPAVIDO and making Eton Cares available to all patients. By bringing IMPAVIDO into Eton’s rare disease commercial infrastructure, we can pair this important therapy with high-touch services designed to help support healthcare providers and expand access for patients. We believe this comprehensive approach will help ensure that patients who need IMPAVIDO can access and initiate treatment without unnecessary delays. We are also working to expand hospital on-site availability across the United States through our consignment inventory stocking program,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.

Clinicians seeking to prescribe IMPAVIDO can e-prescribe by selecting Anovo #5 (Memphis) or fax a patient referral form to 855-813-2039. Patients with questions regarding their prescription or healthcare providers can call Anovo at the dedicated IMPAVIDO line 877-469-4078.

Hospital pharmacies seeking IMPAVIDO for inpatient use may contact Anovo Specialty Pharmacy to establish access through the hospital network.

For urgent or time-sensitive patient needs, Anovo will coordinate an emergency access pathway with treating clinicians, CDC representatives, and hospital pharmacies. The pathway is designed to evaluate the fastest available source of product and delivery option based on the patient’s need-by time and the treating institution’s location.

Additional product details can be found on the product website, www.impavidous.com.

Important Safety Information for IMPAVIDO

INDICATION

IMPAVIDO® (miltefosine) is an antileishmanial drug indicated in adults and adolescents ≥12 years of age weighing ≥30 kg (66 lbs) for treatment of:

• Visceral leishmaniasis due to Leishmania donovani.
• Cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis.
• Mucosal leishmaniasis due to Leishmania braziliensis.

Limitations of Use: Leishmania species evaluated in clinical trials were based on epidemiologic data. There may be geographic variation in the response of the same Leishmania species to IMPAVIDO. The efficacy of IMPAVIDO in the treatment of other Leishmania species has not been evaluated.

IMPORTANT SAFETY INFORMATION

Contraindications

IMPAVIDO is contraindicated in pregnancy because it may cause fetal harm; in patients with Sjögren-Larsson syndrome; and in patients with hypersensitivity to miltefosine or any component of the formulation.

Warnings and Precautions

Embryo-Fetal Toxicity: IMPAVIDO may cause fetal harm when administered during pregnancy. Obtain a pregnancy test before initiating therapy in females of reproductive potential. Advise females of reproductive potential to use effective contraception during treatment and for 5 months after completion of therapy. If vomiting or diarrhea occurs during treatment, oral contraceptive effectiveness may be reduced; advise use of an additional non-hormonal contraceptive method.

Reproductive Effects: Miltefosine caused impaired fertility in animal studies. The potential effects on human fertility have not been adequately evaluated.

Renal Effects: Monitor serum creatinine during treatment and for 4 weeks after completion of therapy.

Hepatic Effects: Monitor liver transaminases and bilirubin during treatment.

Gastrointestinal Effects: Vomiting and diarrhea are common and may result in dehydration. Encourage adequate fluid intake during treatment.

Thrombocytopenia: Monitor platelet counts during therapy in patients treated for visceral leishmaniasis.

Stevens-Johnson Syndrome: Stevens-Johnson syndrome has been reported. Discontinue IMPAVIDO if an exfoliative or bullous rash develops.

Adverse Reactions

The most common adverse reactions (≥2%) are nausea, vomiting, diarrhea, headache, decreased appetite, dizziness, abdominal pain, pruritus, somnolence, elevated transaminases, and elevated serum creatinine.

To report a suspected adverse event related to IMPAVIDO, contact Eton Pharmaceuticals, Inc. at 1-855-224-0233 or the U.S. Food and Drug Administration (FDA) at www.fda.gov/MedWatch or call 1-800-FDA-1088.

Please see Full Prescribing Information, including Boxed Warning regarding Embryo-Fetal Toxicity.

About Eton Pharmaceuticals

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eleven commercial rare disease products: KHINDIVI^® (hydrocortisone), INCRELEX^® (mecasermin), ALKINDI SPRINKLE^® (hydrocortisone), DESMODA^™ (desmopressin acetate), GALZIN^® (zinc acetate), HEMANGEOL^® (propranolol hydrochloride), PKU GOLIKE^®, IMPAVIDO^® (miltefosine), Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: AMGLIDIA^® (glyburide), ASN-001, ET-700, ET-800, and ZENEO^® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) — FTAI Energy Partners LLC (“Jefferson” or the “Company”), a subsidiary of FTAI Infrastructure Inc. (NASDAQ: FIP), today announced that its subsidiary has entered into a definitive agreement to acquire the Port Arthur Terminal in Port Arthur, Texas, and a 50% interest in the Diluent Recovery Unit (“DRU”) located in Hardisty, Alberta, from a subsidiary of USD Group LLC (“USDG”). The total acquisition consideration is approximately $255 million in cash and will be financed by assuming existing indebtedness of the acquired business and with an acquisition debt facility secured by Jefferson and its subsidiaries. The Company expects the acquired assets to generate approximately $50 million of annual EBITDA over the next twelve months. Closing of the transaction is subject to the receipt of required regulatory approvals which are expected during the fourth quarter of 2026.

“The acquisition of USD’s assets is an ideal fit and highly accretive for our Jefferson segment, more than doubling Jefferson’s existing Adjusted EBITDA with contracted cash flow under a long-term agreement with minimum volume commitments from an investment grade counterparty. The transaction significantly de-leverages Jefferson’s balance sheet and, we believe, creates substantial incremental value at Jefferson” said Ken Nicholson, Chief Executive Officer of FTAI Infrastructure.

The acquired assets represent an integrated origin-to-destination logistics platform for the shipment of crude oil into the Beaumont refinery hub under a long-term, take-or-pay contract with a major energy exploration and production company. The Port Arthur Terminal is designed to handle approximately 50,000 barrels per day of crude oil arriving by rail which is further shipped to customers via an owned 12-mile, 24-inch diameter pipeline system connecting to P66’s Beaumont terminal for distribution to local refiners in Beaumont, Lake Charles and other key Gulf Coast markets.

Hank Alexander, CEO of Jefferson said, “Combining the USDG assets with our existing Jefferson terminals is a game-changer for our platform, adding a new long-term customer to our revenue base and providing multiple growth opportunities ahead. We look forward to working with USDG’s team of high quality professionals to continue to grow the acquired assets as well as our existing Jefferson business.”

Jefferson has obtained a commitment for acquisition financing which will enable it to fund the acquisition. In addition, the Company expects to evaluate combining the acquired assets with its existing subsidiary, Jefferson Bond Borrower LLC, which presently owns Jefferson’s main terminal business and a portion of the Jefferson South terminal, and funding the acquisition with the issuance of Additional Parity Bonds under the indenture for Jefferson Bond Borrower LLC.

Jefferies and Houlihan Lokey served as financial advisors to the Company and USDG, respectively. Barclays served as capital finance advisor to Jefferson in connection with arranging funding for the transaction. Vinson & Elkins LLP, Bennett Jones LLP and Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisors to the Company, and Gibson, Dunn & Crutcher LLP acted as legal advisors to USDG.

About Jefferson Energy Companies

Jefferson is a midstream energy infrastructure company headquartered in Houston, Texas, with terminal operations at the Port of Beaumont, one of North America’s largest refining and petrochemical centers. Jefferson Energy’s multimodal terminal facilities provide transloading, storage, handling, blending, and related services for products including crude oil, refined products, and ammonia, with direct access to rail, highway, and marine transportation.

About FTAI Infrastructure Inc.

FTAI Infrastructure Inc. primarily invests in critical infrastructure with high barriers to entry across the rail, ports and terminals, and power and gas sectors that, on a combined basis, generate strong and stable cash flows with the potential for earnings growth and asset appreciation. FTAI Infrastructure is externally managed by an affiliate of Fortress Investment Group LLC, a leading, diversified global investment firm.

Non-GAAP Metrics

EBITDA is defined as net income (loss) attributable to stockholders, adjusted to exclude the impact of provision for (benefit from) income taxes, depreciation and amortization expense and interest expense. Jefferson is not providing forward looking guidance for U.S. GAAP reported financial measures or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable U.S. GAAP measure because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items without unreasonable effort. These items include, but are not limited to, interest expense, contractor costs and customer revenues. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected closing of the transaction, anticipated financing arrangements, projected EBITDA, future operating performance, expected strategic benefits, customer demand, market conditions and anticipated growth opportunities. These statements are based on management’s current expectations and beliefs and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Factors that could cause actual results to differ materially include, among others, the satisfaction of closing conditions, regulatory approvals, financing availability, market conditions, commodity price volatility, customer demand and other risks described in the filings of FTAI Infrastructure Inc. with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements except as required by law.

For further information please contact:

Alan Andreini
Investor Relations
FTAI Infrastructure Inc.
(646) 734-9414

NEWPORT BEACH, CA, Sept. 28, 2026 (GLOBE NEWSWIRE) — Bimergen Energy Corporation (NYSE American: BESS) (“Bimergen”), a U.S. energy infrastructure developer, owner and operator, announces that its Board of Directors has authorized an open-market warrant repurchase program to buyback any or all its publicly traded warrants (Ticker: BESSWS).

The program aims to opportunistically deploy capital to reduce future equity dilution while capitalizing on the then current market pricing. Under the authorization, the Company may purchase warrants from time to time on the open market, through block trades, or via privately negotiated transactions in each case in compliance with applicable federal securities laws, including Sections 9(a)(2) and 10(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules thereunder, SEC rules and regulations, and NYSE American requirements. The timing and actual volume of repurchases will depend on prevailing market conditions, liquidity, and trading volumes and applicable regulatory requirements as determined by management. The program does not obligate the Company to acquire any specific amount of warrants and may be suspended or discontinued at any time.

“We have not yet established brokerage accounts to execute the authorized warrant buyback,” said Bob Brilon, Co-CEO of Bimergen Energy. “By the Board authorizing this open-market buyback program, we as management, can be ready to efficiently use our cash positions to reduce potential dilution, optimize our equity architecture, and build long-term value for our common stockholders as appropriate.”

“Closing transactions for high-quality battery energy storage projects is our focused strategy,” said Cole W. Johnson, Co-CEO of Bimergen Energy. “The flexibility of the buyback program and reduction of equity overhang is viewed as a positive by current and potential strategic partners.”

About Bimergen Energy Corporation

Bimergen Energy Corporation (NYSE American: BESS) is a U.S.-based renewable energy developer, asset owner and operator focused on utility-scale battery energy storage system (BESS) projects. The operating revenue generation comes from buying energy at lower off-peak prices and selling them back to the same grid at higher peak prices. Bimergen develops and operates infrastructure designed to enhance grid stability and support the integration of renewable generation across key U.S. markets, maintaining a diversified pipeline and partnering with institutional capital providers to advance projects through construction and long-term operation. Learn more at www.Bimergen.com.

Forward Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Bimergen Energy Corporation’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the public offering filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Bimergen Energy Corporation undertakes no duty to update such information except as required under applicable law.

Contact:
RedChip Companies Inc.
1-407-644-4256 | 1-800-REDCHIP (733-2447)
BESS@redchip.com

Company Announcement

Copenhagen, 28 September 2026
No. 60/2026

Transactions in connection with share buyback programme
ISS A/S, a leading workplace experience and facility management company, announced on 19 February 2026 a new share buyback programme, see company announcement no. 10/2026. The share buyback programme is executed in accordance Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 (the “Market Abuse Regulation”) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, also referred to as the Safe Harbour Regulation.

Through the programme, ISS wishes to redistribute excess cash to shareholders. The purpose of the share buy-back programme is to (i) reduce the share capital and (ii) meet obligations arising from ISS’ share-based incentive programmes.

Under the programme, ISS will repurchase shares for a maximum consideration of DKK 3.1 billion, including approx. DKK 1.25 billion related to the completed first tranche, over a 12-month period from 19 February 2026 to 22 February 2027 at the latest, both days inclusive. The second tranche of up to DKK 1.85 billion commenced on 11 August 2026 and will complete no later than 22 February 2027.

The following transactions have been made under the programme:

	Number of shares	Average purchase price, DKK	Transaction value, DKK
Accumulated, last announcement	6,253,702	261.02	1,632,341,574
21 September 2026	40,000	292.41	11,696,400
22 September 2026	35,000	298.67	10,453,450
23 September 2026	35,000	303.43	10,620,050
24 September 2026	66,000	298.74	19,716,840
25 September 2026	66,000	293.88	19,396,080
Accumulated under the programme	6,495,702	262.36	1,704,224,394

Following the transactions stated above, ISS A/S owns a total of 6,244,077 treasury shares corresponding to 3.90% of the total share capital.

In accordance with the Market Abuse Regulation, the details of each transaction made under the share buyback programme are enclosed.

For investor enquiries
Michael Vitfell-Rasmussen, Head of Group Investor Relations, +45 53 53 87 25
Anne Sophie Riis, Senior Investor Relations Manager, +45 30 52 94 68

For media enquiries
Charlotte Holm, Head of External Communication, +45 41 76 19 89

ISS is a leading, global provider of workplace and facility service solutions. In partnership with customers, ISS drives the engagement and well-being of people, minimises the impact on the environment, and protects and maintains property. ISS brings all of this to life through a unique combination of data, insight and service excellence at offices, factories, airports, hospitals and other locations across the globe. ISS has more than 325,000 employees around the globe, who we call “placemakers”. In 2025, Group revenue was DKK 84.7 billion. For more information on the ISS Group, visit www.issworld.com

Attachments

• ISS announcement – SBB week 39
• Appendix_Company_Announcement_NO_39-2026

InstallatørGruppen’s Interim trading statement for the period ending 30 September will be published around 08:00 CEST on 28 October 2026.

The report will be presented on the same day at 10:00 CEST by Group CEO Niels Eldrup Meidahl and Group CFO Mathias Ringsted Grüner. The presentation will be held in English and can be followed on the web or by phone. The presentation will be followed by a Q&A session.

Link to webcast

Telephone conference: To participate and ask questions in the conference call, please register via this link.

The report and presentation will be available here

For further information, please contact: Maximillian Hjorth Beste, Head of M&A and Investor Relations Telephone: +45 2899 2846 E-mail: mhb@i-g.dk

Transaction in Own Shares

September 25, 2026

• • • • • • • • • • • • • • • •

Shell plc (the ‘Company’) announces that on 25 September 2026 it purchased the following number of Shares for cancellation.

Aggregated information on Shares purchased according to trading venue:

Date of Purchase	Number of Shares purchased	Highest price paid	Lowest price paid	Volume weighted average price paid per share	Venue	Currency
25/09/2026	476,225	£ 36.3300	£ 35.8100	£ 36.0073	LSE	GBP
25/09/2026	–	–	–	–	Chi-X (CXE)	GBP
25/09/2026	–	–	–	–	BATS (BXE)	GBP
25/09/2026	300,000	€ 42.3250	€ 41.7850	€ 41.9518	XAMS	EUR
25/09/2026	–	–	–	–	CBOE DXE	EUR
25/09/2026	–	–	–	–	TQEX	EUR

These share purchases form part of the on- and off-market limbs of the Company’s existing share buy-back programme previously announced on 30 July 2026. 

In respect of this programme, Goldman Sachs International will make trading decisions in relation to the securities independently of the Company for a period from 30 July 2026 up to and including 23 October 2026.

The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market. The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein. The programme will be conducted in accordance with Chapter 9 of the UK Listing Rules and Article 5 of the Market Abuse Regulation 596/2014/EU dealing with buy-back programmes (“EU MAR”) and EU MAR as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020)  through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time (“UK MAR”) and the Commission Delegated Regulation (EU) 2016/1052 (the “EU MAR Delegated Regulation”) and the EU MAR Delegated Regulation as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time.

In accordance with EU MAR and UK MAR, a breakdown of the individual trades made by Goldman Sachs International on behalf of the Company as a part of the buy-back programme is detailed below.

Enquiries:

Media International: +44 (0) 207 934 5550; U.S. and Canada: https://www.shell.us/about-us/news-and-insights/media/submit-an-inquiry.html

Attachment

• 20260925_Shell RNS – full version

Company announcement
No. 60/2026

                                                 28 September 2026

Transactions in connection with share buyback programme
On 3 February 2026, Netcompany Group A/S (“Netcompany”) announced that a share buyback programme of up to DKK 750m and a maximum of 3,250,000 shares had been initiated with the purpose of adjusting Netcompany’s capital structure and meeting its obligations relating to share-based incentive programmes.

The share buyback programme is executed in accordance with EU Market Abuse Regulation, EU Regulation no. 596/2014 of 16 April 2014 and the provisions of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Regulation”). The share buyback programme will end no later than 29 January 2027.

Transactions made under the share buyback programme will be announced through Nasdaq Copenhagen on a weekly basis.

The following transactions have been executed in the period 21 September 2026 to 25 September 2026:

	Number of shares	Average purchase price, DKK	Transaction value, DKK
21/09/2026	17,000	320.47	5,448,021
22/09/2026	8,000	318.95	2,551,586
23/09/2026	1,000	323.68	323,683
24/09/2026	22,500	311.75	7,014,308
25/09/2026	2,500	309.72	774,298
Accumulated for the period	51,000	–	16,111,895
Accumulated under the programme	1,444,177	–	477,069,610

Detailed information on all transactions under the share buyback programme during the period is included in the attached appendix.

Following the above transactions and vesting of restricted share units, Netcompany owns a total of 1,794,396 treasury shares corresponding to 3.9% of the total share capital.

Additional information
For additional information, please contact:

Netcompany Group A/S
Thomas Johansen, CFO, +45 51 19 32 24
Frederikke Linde, Head of IR, +45 60 62 60 87

Attachments

• 60. Netcompany – Transactions in connection with share buyback programme
• 60. Appendix – Information on all transactions

RENO, Nev., Sept. 28, 2026 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE American: LODE) (“Comstock” and the “Company”) will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.

Company Webcast

The webcast presentation will take place at 12:45 p.m. ET on Tuesday, September 29, 2026. The webcast can be accessed by visiting the conference website at https://lythampartners.com/fall2026/ or directly at https://app.webinar.net/LkZJEPN6PnK. The webcast will also be available for replay following the event.

1×1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1×1@lythampartners.com or register for the event at https://lythampartners.com/fall2026invreg/.   

About Comstock Inc.

Comstock Inc. (NYSE: LODE) innovates and commercializes technologies, systems and supply chains that enable, support and sustain clean energy systems by efficiently, effectively, and expediently extracting and converting under-utilized natural resources into reusable metals, like silver, aluminum, gold, and other critical minerals, primarily from end-of-life photovoltaics and renewable fuels, chemicals and animal feedstocks, primarily derived from proprietary crops and other forms of woody biomass for energy.

To learn more, please visit www.comstock.inc.

Comstock Social Media Policy

Comstock Inc. has used, and intends to continue using, its investor relations link and main website at www.comstock.inc in addition to its X.com, LinkedIn and YouTube accounts, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts

For investor inquiries:
Judd B. Merrill, Chief Financial Officer
Tel (775) 413-6222
ir@comstockinc.com

For media inquiries:
Zach Spencer, Director of External Relations
Tel (775) 847-7573
media@comstockinc.com

Forward-Looking Statements 

This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “forecast,” “seek,” “target,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future market conditions; future financial, natural, and social gains; future prices and sales of, and demand for, our products and services; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land and asset sales; investments, acquisitions, joint ventures, strategic alliances and business combinations; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings of equity or debt securities; and future working capital needs, revenues, variable costs, throughput rates, operating expenses, debt levels, cash flows, margins, taxes and earnings. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company or any other issuer.